---
schema_version: "secwatch.filing_event.v1"
accession: "0001087294-26-000015"
form_type: "8-K"
ticker: "CPIX"
cik: "0001087294"
company_name: "CUMBERLAND PHARMACEUTICALS INC"
filed_at: "2026-03-03T23:59:59+00:00"
generated_at: "2026-05-15T21:59:20.487911+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cumberland Pharma reports Q4 revenue up 31% to $13.7M; full-year adjusted earnings $1.7M

## Summary
- Full-year 2025 net revenue $44.5M (+18% YoY); net loss improved to $2.9M from $6.5M.
- Adjusted earnings for 2025 were $1.7M vs. -$1.0M in 2024; operating cash flow $4.9M.
- Debt reduced by $10M; credit facility balance $5.2M at year-end; shareholders equity $24.9M.
- Vibativ approved in China; launched in Saudi Arabia; Talicia co-commercialization began Oct 2025.
- Caldolor received permanent J-code (J1741) for CMS reimbursement in Dec 2025.

## SEC filing metadata
- accession: 0001087294-26-000015
- form_type: 8-K
- ticker: CPIX
- cik: 0001087294
- company_name: CUMBERLAND PHARMACEUTICALS INC
- filed_at: 2026-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1087294/000108729426000015/0001087294-26-000015-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1087294/000108729426000015/cpix-20260303.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001087294-26-000015
- JSON: https://secwatch.observer/filing/0001087294-26-000015.json
- Plain text: https://secwatch.observer/filing/0001087294-26-000015.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.